Literature DB >> 8086764

Intra- and extracerebral blood flow changes and flushing after intravenous injection of human corticotropin-releasing hormone.

A Kübler1, G Rothacher, V A Knappertz, G Krämer, M Nink, J Beyer, H Lehnert.   

Abstract

To study facial flush after systemic administration of human corticotropin-releasing hormone (hCRH) we injected 100 micrograms hCRH intravenously to ten healthy young men. The increase in facial temperature was measured by infrared camera. A significant increase in facial temperature of 1.39 degrees C +/- 0.3 was found within 7 min in all patients, which lasted up to 60 min, although facial flushing was visible in only 50% (5/10) of the probands. In a second experiment 100 micrograms hCRH was then administered to seven other healthy young men. Intra- and extracerebral blood flow velocity changes in the medial cerebral artery (MCA) and external carotid artery (ECA) were measured after hCRH administration by use of Doppler sonography. We found a decrease of intracerebral blood flow which was caused by hyperventilation and was reversible following 6% CO2 hyperventilation during a second injection of 100 micrograms hCRH. Blood flow velocity in the ECA increased by 111.5 +/- 32.9% (compared to baseline level), lasted up to 60 min after hCRH injection, and was not reversible by 6% end-tidal CO2 ventilation. We thus demonstrated that the direct vasodilatory effect of hCRH involves the ECA-supplied vascular territory only. The intracerebral vasoconstrictory effect represents the result of hyperventilation following hCRH injection. The data thus clearly suggest an interaction of hCRH and the vascular endothelium of the ECA, causing a marked blood flow velocity increase and facial flushing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086764     DOI: 10.1007/bf00252822

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  28 in total

Review 1.  Safety and side effects of human and ovine corticotropin-releasing hormone administration in man.

Authors:  M Nink; U Krause; H Lehnert; J Beyer
Journal:  Klin Wochenschr       Date:  1991-03-18

Review 2.  Physiology and pharmacology of corticotropin-releasing factor.

Authors:  M J Owens; C B Nemeroff
Journal:  Pharmacol Rev       Date:  1991-12       Impact factor: 25.468

3.  Transcranial measurement of blood velocities in the basal cerebral arteries using pulsed Doppler ultrasound: velocity as an index of flow.

Authors:  F J Kirkham; T S Padayachee; S Parsons; L S Seargeant; F R House; R G Gosling
Journal:  Ultrasound Med Biol       Date:  1986-01       Impact factor: 2.998

4.  Effects of synthetic ovine CRF on ACTH, cortisol and blood pressure in sheep.

Authors:  N H Kalin; J C Gonder; S E Shelton
Journal:  Peptides       Date:  1983 Mar-Apr       Impact factor: 3.750

5.  Studies on facial temperature rise and involvement of serotonin in the respiratory stimulation by CRH.

Authors:  U Krause; M Nink; A Brauer; I Huber; A Velten; H Lehnert; J Beyer
Journal:  Horm Metab Res       Date:  1991-10       Impact factor: 2.936

6.  Amunine (ovine CRF), urotensin I and sauvagine, three structurally-related peptides, produce selective dilation of the mesenteric circulation.

Authors:  K L MacCannell; K Lederis; P L Hamilton; J Rivier
Journal:  Pharmacology       Date:  1982       Impact factor: 2.547

7.  Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion.

Authors:  T H Schürmeyer; P C Avgerinos; P W Gold; W T Gallucci; T P Tomai; G B Cutler; D L Loriaux; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

8.  Hypotensive effects of ovine and human corticotrophin-releasing factors in man.

Authors:  A R Hermus; G F Pieters; J J Willemsen; H A Ross; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Corticotropin releasing factor (CRF)-stimulation test in normal controls and patients with disturbances of the hypothalamo-pituitary-adrenal axis.

Authors:  O A Müller; H G Dörr; B Hagen; G K Stalla; K von Werder
Journal:  Klin Wochenschr       Date:  1982-12-15

10.  Effects of corticotropin-releasing hormone on the postoperative course of elderly patients under long-term artificial respiration.

Authors:  M Nink; J Beyer; U Krause; F Holzhauer; T Junginger; H Lehnert
Journal:  Acta Endocrinol (Copenh)       Date:  1992-09
View more
  3 in total

Review 1.  Mast cells and inflammation.

Authors:  Theoharis C Theoharides; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Danae-Anastasia Delivanis; Nikolaos Sismanopoulos; Bodi Zhang; Shahrzad Asadi; Magdalini Vasiadi; Zuyi Weng; Alexandra Miniati; Dimitrios Kalogeromitros
Journal:  Biochim Biophys Acta       Date:  2010-12-23

2.  Urocortin-induced endothelium-dependent relaxation of rat coronary artery: role of nitric oxide and K+ channels.

Authors:  Yu Huang; Franky Leung Chan; Chi-Wai Lau; Suk-Ying Tsang; Guo-Wei He; Zhen-Yu Chen; Xiaoqiang Yao
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Inhibition of pituitary-adrenal secretion by a corticotropin releasing hormone antagonist in humans.

Authors:  T Z Baram; W G Mitchell; E Haden
Journal:  Mol Psychiatry       Date:  1996-09       Impact factor: 15.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.